Vertex Pharmaceuticals Says FDA Approves Expanded Use of Casgevy in Younger Children With Blood Disorders
MT Newswires Live
Jul 02
Vertex Pharmaceuticals (VRTX) said late Wednesday the US Food and Drug Administration has expanded its approval of Casgevy to treat children aged two years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
The expanded label lowers the minimum eligible age from 12 years and makes about 5,500 additional children in the US eligible for the one-time therapy, the company said.
Vertex Pharmaceuticals added regulatory reviews for label expansion are currently underway in the UK and Saudi Arabia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.